Not available
Quote | Celcuity Inc. (NASDAQ:CELC)
Last: | $21.60 |
---|---|
Change Percent: | 0.88% |
Open: | $18 |
Close: | $21.60 |
High: | $22.188 |
Low: | $17.67 |
Volume: | 605,554 |
Last Trade Date Time: | 03/28/2024 03:00:00 am |
News | Celcuity Inc. (NASDAQ:CELC)
2024-03-28 08:00:08 ET Gil Blum from Needham issued a price target of $24.00 for CELC on 2024-03-28 07:08:00. The adjusted price target was set to $24.00. At the time of the announcement, CELC was trading at $18.16. CELC currently trades -4.12% versus its 52 week high of...
2024-03-27 18:40:09 ET Celcuity Inc. (CELC) Q4 2023 Earnings Conference Call March 27, 2024 4:30 p.m. ET Company Participants Maria Yonkoski - ICR Westwicke Brian Sullivan - Chief Executive Officer and Co-Founder Vicky Hahne - Chief Financial Officer Igor Gor...
Message Board Posts | Celcuity Inc. (NASDAQ:CELC)
Subject | By | Source | When |
---|---|---|---|
Tiny float just under 6 million. Moves quick | Natureboy1 | investorshub | 04/12/2021 2:52:45 PM |
A.H. ACTED LIKE HALT IN TRADING 'Celcuity' $CELE | mick | investorshub | 04/10/2021 3:49:45 PM |
I HAD TO DO SAME 'Celcuity' NEED QUOTES | mick | investorshub | 04/10/2021 3:46:13 PM |
Is that why I had to call the | Natureboy1 | investorshub | 04/10/2021 11:08:48 AM |
Looks like youve already 5xd your investment. | Natureboy1 | investorshub | 04/10/2021 11:05:53 AM |
News, Short Squeeze, Breakout and More Instantly...
2024-03-28 08:00:08 ET Gil Blum from Needham issued a price target of $24.00 for CELC on 2024-03-28 07:08:00. The adjusted price target was set to $24.00. At the time of the announcement, CELC was trading at $18.16. CELC currently trades -4.12% versus its 52 week high of...
Dosed the first patient in a Phase 1b/2 trial evaluating gedatolisib in combination with darolutamide for the treatment of metastatic castration resistant prostate cancer Presented nonclinical data demonstrating the superior therapeutic effects of gedatolisib compared to other PI3K/AKT/mT...
Cano Health Inc. Class A (CANOQ) is expected to report for Q4 2023 Cathay Pacific Airways Ltd. ADR (CPCAY) is expected to report for Q4 2023 NeuroSense Therapeutics Ltd. (NRSN) is expected to report for quarter end 2023-12-31 Bayerische Motoren Werke AG (BAMXF) is expected to report f...